Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival

Circulation

Volumn 116, Issue 6, 2007, Pages 613-618

  Leeper, Nicholas J ^a,b   Ardehali, Reza ^a   DeGoma, Emil M ^a   Heidenreich, Paul A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lipids; Morbidity; Mortality; Statins; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN; STATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DYSLIPOPROTEINEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL; TERTIARY HEALTH CARE; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL RATE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 34548156789     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.694117     Document Type: Article

References (15)

1. Baigent C, Keech A, Kearny PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350: 1495-1504.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotta AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipids lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
4. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pederson TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; A-to-Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A-to-Z trial. JAMA. 2004;292:1307-1316.
5. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
6. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy, a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-1416.
7. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D; Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992;152:1490 -1500.
8. Oliver MF. Might treatment of hypercholesterolemia increase noncardiac mortality? Lancet. 1991;337:1529-1531.
9. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046-1060.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published erratum appears in Circulation. 2004;110:763]. Circulation. 2004;110:227-239.
11. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-445.
12. Austin PC, Mamdani MM. Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation. 2005;112:1296 -1300.
13. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndrome trials? Am J Cardiol. 2006;98:S18 -S25.
14. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007;46:1-9.
15. Fisman EZ, Adler Y, Tenenbaum A. Statins research unfinished saga: desirability versus feasibility. Cardiovasc Diabetol. 2005;4:8.